DE4132296C1 - Enzymic metabolic prod. prepn. for intestinal disorders etc. - obtd. from pathogenic lacto- and bifido- bacteria from the gut - Google Patents
Enzymic metabolic prod. prepn. for intestinal disorders etc. - obtd. from pathogenic lacto- and bifido- bacteria from the gutInfo
- Publication number
- DE4132296C1 DE4132296C1 DE4132296A DE4132296A DE4132296C1 DE 4132296 C1 DE4132296 C1 DE 4132296C1 DE 4132296 A DE4132296 A DE 4132296A DE 4132296 A DE4132296 A DE 4132296A DE 4132296 C1 DE4132296 C1 DE 4132296C1
- Authority
- DE
- Germany
- Prior art keywords
- vegetable
- mass
- lactic acid
- fermentation
- vegetable mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000001717 pathogenic effect Effects 0.000 title claims description 5
- 241000186000 Bifidobacterium Species 0.000 title claims 2
- 230000002503 metabolic effect Effects 0.000 title description 4
- 208000028774 intestinal disease Diseases 0.000 title 1
- 235000013311 vegetables Nutrition 0.000 claims abstract description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims abstract description 11
- 229930003231 vitamin Natural products 0.000 claims abstract description 8
- 235000013343 vitamin Nutrition 0.000 claims abstract description 8
- 239000011782 vitamin Substances 0.000 claims abstract description 8
- 229940088594 vitamin Drugs 0.000 claims abstract description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 6
- 238000000855 fermentation Methods 0.000 claims abstract description 6
- 230000004151 fermentation Effects 0.000 claims abstract description 6
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 6
- 239000004310 lactic acid Substances 0.000 claims abstract description 6
- 235000021537 Beetroot Nutrition 0.000 claims abstract description 5
- 241001456088 Hesperocnide Species 0.000 claims abstract description 4
- 240000001949 Taraxacum officinale Species 0.000 claims abstract description 4
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 4
- 235000009108 Urtica dioica Nutrition 0.000 claims abstract description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 4
- 239000011707 mineral Substances 0.000 claims abstract description 4
- 235000020681 well water Nutrition 0.000 claims abstract description 4
- 239000002349 well water Substances 0.000 claims abstract description 4
- 244000000626 Daucus carota Species 0.000 claims abstract description 3
- 235000002767 Daucus carota Nutrition 0.000 claims abstract description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 3
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 3
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract 3
- 240000001890 Ribes hudsonianum Species 0.000 claims abstract 2
- 235000016954 Ribes hudsonianum Nutrition 0.000 claims abstract 2
- 235000001466 Ribes nigrum Nutrition 0.000 claims abstract 2
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract 2
- 229960005070 ascorbic acid Drugs 0.000 claims abstract 2
- 239000011668 ascorbic acid Substances 0.000 claims abstract 2
- 239000012141 concentrate Substances 0.000 claims abstract 2
- 238000010303 mechanochemical reaction Methods 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 230000002255 enzymatic effect Effects 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 13
- 239000002207 metabolite Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 7
- 230000000968 intestinal effect Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 4
- 230000003068 static effect Effects 0.000 claims description 3
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 235000021014 blueberries Nutrition 0.000 claims description 2
- 235000014134 echinacea Nutrition 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 235000012907 honey Nutrition 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 244000286916 Ratibida columnifera Species 0.000 claims 1
- 235000009413 Ratibida columnifera Nutrition 0.000 claims 1
- 239000005862 Whey Substances 0.000 claims 1
- 102000007544 Whey Proteins Human genes 0.000 claims 1
- 108010046377 Whey Proteins Proteins 0.000 claims 1
- 229940038481 bee pollen Drugs 0.000 claims 1
- 229940043430 calcium compound Drugs 0.000 claims 1
- 150000001674 calcium compounds Chemical class 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 150000002506 iron compounds Chemical class 0.000 claims 1
- 150000003112 potassium compounds Chemical class 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 210000000936 intestine Anatomy 0.000 abstract description 5
- 206010010774 Constipation Diseases 0.000 abstract description 4
- 239000006185 dispersion Substances 0.000 abstract description 4
- 239000000654 additive Substances 0.000 abstract description 3
- 206010016766 flatulence Diseases 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 208000030159 metabolic disease Diseases 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 244000078534 Vaccinium myrtillus Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 239000008267 milk Substances 0.000 abstract 1
- 210000004080 milk Anatomy 0.000 abstract 1
- 235000013336 milk Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000003867 tiredness Effects 0.000 abstract 1
- 208000016255 tiredness Diseases 0.000 abstract 1
- 239000005418 vegetable material Substances 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 244000052616 bacterial pathogen Species 0.000 description 6
- 230000002715 bioenergetic effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001632 homeopathic effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 239000002028 Biomass Substances 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000007102 metabolic function Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KVFJBIQWENJTDM-UHFFFAOYSA-N 1,2-dihydrobenzo[j]aceanthrylene Chemical compound C1=CC2=CC=CC=C2C2=C1C(CCC1=CC=C3)=C1C3=C2 KVFJBIQWENJTDM-UHFFFAOYSA-N 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000037189 immune system physiology Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000036515 potency Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004882 Intestinal Polyposis Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- -1 mmonia Species 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/56—Lactic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Die Erfindung betrifft ein enzymatisches Stoffwechsel produkt.The invention relates to an enzymatic metabolism product.
Die Forderung nach aktiven biologischen Systemen als reparative Mechanismen für den durch toxische Belastung, Immuninsuffizienz, O₂-Utilisations- und Permeabilitäts schäden der Zellmembran, Entgiftungs-, Assimilations- und Stoffwechselstörungen, Candidabefall, Mykosen, Al lergosen, Enzym- und Regelsystemblockaden schwer ange schlagenen menschlichen Organismus ist zwingend. Die Ursachen dieser Schäden des menschlichen Organismus sind in der Regel in einem seit Jahren gestörten oder bereits folgenschwer pathogen veränderten Darmmilieu zu suchen. Die Gründe hierfür sind durch wissenschaftliche Erkenntnisse gesichert. Neben den klassischen Auslö sungsmechanismen, jahrelangem Ernährungsabusus, sind es gerade die iatrogenen Maßnahmen mit Antibiotika, Korti son, kortikoidhaltigen Arzneimitteln, Sulfonamiden, Laxantien, Ovulationshemmern, Immunsuppressiva, Strah len- und Chemotherapie und Medikamentenabusus, die die säurebildende menschliche Darmflora - Symbionten - teil weise oder vollständig eliminieren.The demand for active biological systems as reparative mechanisms for toxic load, Immune insufficiency, O₂ Utilisations- and permeability cell membrane damage, detoxification, assimilation and metabolic disorders, candidiasis, mycoses, Al Lergoses, enzyme and regulatory system blockades difficult beating human organism is compelling. The Causes of this damage to the human organism are usually disturbed in a for years or years already followed pathogenically changed intestinal environment too search. The reasons are scientific Insights secured. In addition to the classic tripping mechanisms, years of nutritional benefit, are just the iatrogenic measures with antibiotics, Korti corticoid medicinal products, sulfonamides, Laxatives, ovulation inhibitors, immunosuppressive drugs, radiation and chemotherapy and drug abuse that the Acid-forming human intestinal flora - symbionts - part wise or completely eliminate.
Die hieraus resultierende Dickdarm-pH-Verschiebung vom Normwert pH 5,8 über pH 6 in Richtung pH 7, also neutral, löst eine rege Stoffwechseltätigkeit der mit eigenen Enzymen ausgestatteten, als obligat pathogen geltenden Keimen wie beispielsweise E. coli, Proteus, Enterobakt. und Clostridien (Fäulnis- und Ammoniakgasbildner) aus, deren Wachstumsoptimum bei pH 6,0 und darüber liegt. Diese obligat pathogenen Keime vermehren sich in diesem pH-Milieu sehr rasch und verstoffwechseln Kohlehydrate zu Ammoniakgas, verhalten sich invasiv und können dann bei anhaltender pH-Verschiebung Zugriff auf den unver dauten Speisebrei im oberen Dünndarm bekommen. Dort spalten sie die Cholsäure (Gallensalze) in Cholanthren um. Ammoniakgas und Cholanthren stellen ein subtoxi sches cancerogenes Potential dar, welches den gesamten Makroorganismus belastet. Das unphysiologisch gewordene Intestinum, das in quantitativer und/oder qualitativer Hinsicht erhebliche Abweichungen von der Norm seiner Keimbesiedlung aufweist, ist klinisch relevant und wird als enterale Dysbiose bezeichnet.The resulting colon pH shift from Standard value pH 5.8 above pH 6 in the direction of pH 7, ie neutral, triggers a brisk metabolic activity of your own Enzyme-equipped, considered obligate pathogenic Germs such as E. coli, Proteus, Enterobakt. and Clostridia (decay and ammonia gas generators), their growth optimum is at pH 6.0 and above. These obligate pathogenic germs multiply in this pH environment very quickly and metabolize carbohydrates to ammonia gas, behave invasively and can then with persistent pH shift access to the un got chyme in the upper small intestine. There split the cholic acid (bile salts) into cholanthrene around. Ammonia gas and cholanthrene provide a subtoxi beautiful carcinogenic potential, which the entire Loaded macroorganism. The unphysiological become Intestinum that is in quantitative and / or qualitative Regards significant deviations from the norm of his Germ colonization is clinically relevant and will referred to as enteral dysbiosis.
Bei pH-Werten um 6,5 kann die quantitative Ausleitung der Toxine aus dem Intestinum nur noch schwerlich erfol gen, so daß die Leber die Entgiftungsfunktion des laten ten Dickdarmentgiftungssystems übernimmt. Es kommt zur Überbelastung der Leber, was wiederum folgenschwere Aus wirkungen auf Galle und Pankreas hat. Das durch die pH- Verschiebung unphysiologisch gewordene Intestinum gewähr leistet nur noch einen ungenügenden Ablauf der Resorp tions-, Assimilation- und Stoffwechselfunktionen. So wer den ebenfalls Lymphblockaden nachgewiesen. At pH values around 6.5, the quantitative leakage the toxins from the intestine only with difficulty so that the liver can detoxify the latency of the liver accep tensive system. It comes to Overloading of the liver, which in turn has serious consequences has effects on bile and pancreas. This through the pH Displacement of the non-physiological intestine only makes an insufficient process of Resorp tion, assimilation and metabolic functions. So who also demonstrated lymph blockades.
Im Verbund der endogenen Intoxikation kommt es insbeson dere über den Mukoseblock zur Latenz der Regelmechanis men des humoralen und zellulären Immunsystems, was die Abwehrlage des Organismus signifikant beeinträchtigt.In the composite of endogenous intoxication it comes in particular over the mucose block to the latency of the Regelmechanis humoral and cellular immune systems, what the Defensive position of the organism significantly impaired.
Die Erfindung stellt sich daher die Aufgabe, ein enzy matisches Stoffwechselprodukt zu ent wickeln, das sicherstellt, daß Entgiftungs-, Resorp tions- und Stoffwechselfunktionen des Darms wieder in einem ausreichenden Maße erfüllt werden und die immuno logischen Abläufe sowie die Selbstheilungskräfte akti viert, so daß Obstipationen, colon irritabile, Völlege fühl, Gasbildung, Flatulenz und Müdigkeit sowie die durch diese Toxinlage erfolgende Auslösung stoffwechsel abhängiger Zivilisationskrankheiten mit ihren gefürchte ten Komplikationen vermieden werden.The invention therefore has the task of enzy matic metabolite ent that ensures detoxification, resorp tion and metabolic functions of the intestine back into be met to a sufficient extent and the immuno logical processes and the self-healing powers akti fourth, so that constipations, colon irritable, fullness feel, gas, flatulence and fatigue as well as the triggering metabolism by this toxin layer dependent civilization diseases with their dread complications are avoided.
Diese Aufgabe wird gemäß Anspruch 1 gelöst.This object is according to claim 1 solved.
Vorteilhafte Ausgestaltungen der Erfindung sind in den Unteransprüchen gekennzeichnet.Advantageous embodiments of the invention are in the Subclaims characterized.
Durch das erfindungsgemäße enzymatische Stoffwechsel produkt wird die natürliche Darmflora wiederhergestellt, indem der in den pH-Wertbereich von über 6,0 entgleiste pH-Wert auf Werte unter 6,0 gesenkt wird, die zur Folge haben, daß unter anderem die Gallensäure dekonjugieren den Clostridienkeime zerstört werden, die Stoffwechsel aktivitäten genommen werden und enzymatische Verstoff wechselungsprozesse ammoniakgasbildender Fäulnisfloren nicht mehr stattfinden. Die kontinuierliche Ansäuerung stoppt somit die Toxinproduktion, der Überhang patholo gischer Keime und die Toxine werden über die Darmlymphe ausgeleitet, wodurch die Leber entlastet wird. By the enzymatic metabolism according to the invention product restores the natural intestinal flora, by derailing in the pH range of over 6.0 pH is lowered to values below 6.0, the result have, inter alia, deconjugate the bile acid The Clostridium germs are destroyed, the metabolism activities are taken and enzymatic Verstoff change processes of ammonia gas-forming decaying floras no longer take place. The continuous acidification thus stops the toxin production, the overhang patholo germs and the toxins are transmitted via the intestinal lymph discharged, which relieves the liver.
Entgiftungs-, Stoffwechsel- und Resorptionsmechanismen werden reanimiert.Detoxification, metabolic and absorption mechanisms are being resuscitated.
Die zahlenmäßig reduzierte Säuerungsflora kann sich bei diesem optimalen pH-Wert wieder vermehren. Die säurebil denden Keime, Immunsysteme und die Selbstheilungskräfte kommen in die Regenerationsphase.The numerically reduced Säuerungsflora can at increase this optimal pH again. The acid bil germs, immune systems and self-healing powers come into the regeneration phase.
Das erfindungsgemäße enzymatische Stoffwechselprodukt bewirkt die Endversorgung der Zellen durch fermentierte Biokatalysatoren in Form eines Wirkstoffkomplexes von Enzymen, Aminosäuren, mikrofein dispergierten Heilpflan zen, Mineralstoffen und Vitaminen. Betazyane aus den Farbkörpern der roten Bete und anderen roten Früchten unterstützen die O₂-Utilisation der Zellen. Das Stoff wechselprodukt ist somit ein Diätetikum, das die Her stellung eines adäquaten, physiologischen Milieus des menschlichen Dickdarms, also eines Milieus unter pH 6,0 bewirkt bei gleichzeitiger Substitution lebensfähiger Mischkulturen, bestehend aus apathogenen darmgleichen Lactobazillen und Bifidusstämmen. Die Anwendung dieses erfindungsgemäßen Diätetikums bewirkt eine Therapie, die als Symbiosesteuerung bezeichnet wird und zu der die Reanimierung der säurebildenden Darmflora bzw. die Neuansiedlung dieser Floren gehört und die parallel zur Therapie der stoffwechselabhängigen Haupterkrankungen, also einer der zahlreichen bekannten Zivilisationskrank heiten wie Obstipation und die darauf basierenden Darm erkrankungen, wie die Dysbiose, persistierende Darment zündungen, die Divertikulose, der Morbus Crohn, die Darmpolyposis, die Colitis und das Carm-Ca. sowie koro nare Herz- und Kreislauferkrankungen inclusive Arterio sklerose und Herzinfarkt, Krebs, Leukämie, Hypertonie, Allergien, Dermatosen, Candidosen und Erkrankungen des rheumatischen Formenkreises u. a. wirkt. The enzymatic metabolite according to the invention causes the final supply of the cells by fermented Biocatalysts in the form of an active substance complex of Enzymes, amino acids, microfine dispersed medicinal plant zen, minerals and vitamins. Betazyans from the Color bodies of beetroot and other red fruits support the O₂ utilization of the cells. The substance Alternate product is thus a dietetic that the Her position of an adequate, physiological milieu of the human colon, ie a milieu below pH 6.0 causes with simultaneous substitution viable Mixed cultures consisting of non-pathogenic ones Lactobacilli and bifiduts. The application of this dietetic according to the invention causes a therapy, which is referred to as symbiosis control and to the the resuscitation of the acid-forming intestinal flora or the Resettlement of these floras belongs and which parallel to Treatment of metabolic-dependent major diseases, So one of the numerous known civilization disease such as constipation and the intestine based on it diseases, such as dysbiosis, persistent intestine inflammations, diverticulosis, Crohn's disease, the Intestinal polyposis, colitis and Carm-Ca. as well as koro nare cardiovascular diseases including arterio sclerosis and myocardial infarction, cancer, leukemia, hypertension, Allergies, dermatoses, candidoses and diseases of the Rheumatic Formenkreises u. a. acts.
Das Verfahren zur Herstellung des enzymatischen Stoff wechselprodukts bedient sich der mikrofeinen Zerkleine rung bzw. Zerlegung der Bestandteile der vegetabilen Masse durch einen oder mehrere bekannte Desintegratoren, die auf das vegetabile Massengemisch mechanische Schlä ge ausüben, und zwar gemäß einer vorteilhaften Verfah rensvariante bei gleichzeitiger Einwirkung eines stati schen und/oder dynamischen Magnetfeldes oder eines elek trischen Spannungsfeldes auf die vegetabile Masse.The process for the preparation of the enzymatic substance change product uses the microfine shredded tion or decomposition of the components of the vegetable Mass by one or more known disintegrators, which on the vegetable mass mixture mechanical Schlä ge exercise, according to an advantageous Verfah variant with simultaneous action of a stati and / or dynamic magnetic field or an elec tense field of tension on the vegetable mass.
Derartige Verfahren sind zur mechanischen Wasserbehand lung bekannt geworden (DE-OS 30 04 664), dienen jedoch dort zur Steuerung der Eigenschaften des Wassers durch Beeinflussung der molekularen Struktur durch Frequenz einwirkung mittels mechanischer Schläge, vorzugsweise von definierter Stärke, Zahl und Zeitfolge, um das Was ser zum Zwecke der Steigerung seiner Lösungsfähigkeit für ohne spezielle Zusätze schwer bis nicht lösbare oder emulgierbare Substanzen zu beeinflussen. Dabei ist daran gedacht, die Eigenschaften des Wassers als Wasch- und Reinigungsmittel auch ohne oder mit wesentlich ver minderten Zugaben von Netzmitteln und konditionierenden Mitteln zu verbessern, insbesondere für Fette aufnahme fähiger zu machen.Such methods are for mechanical water treatment ment become known (DE-OS 30 04 664), but serve there to control the properties of the water Influence of the molecular structure by frequency action by means of mechanical impacts, preferably of defined strength, number and time sequence, around the what for the purpose of increasing its solubility for difficult to not soluble without special additives or to influence emulsifiable substances. It is thinking about using the properties of water as a washing and detergents even without or with significantly ver reduced additions of wetting agents and conditioning Improve funds, especially for fat intake to make more capable.
Das Verfahren, bei dem die vegetabile Masse in einer Gesamtmenge von 10 bis 20 Gew.-% in der wäßrigen Lösung vorliegt und diese Masse sowie die Zuta ten vor der Vergärung in die Desintegrationseinrichtung eingefüllt werden, verfolgt eine andere Richtung, indem die Schlagwirkung des oder der Desintegratoren eine mi krofeine Zerkleinerung und damit einen entsprechenden Aufschluß der Substanzen bewirken soll, aus denen die vegetabile Masse zusammengesetzt ist, um die Wirksamkeit dieser Substanzen zu erhöhen und ihre gegenseitige Rea genz zu verstärken und dadurch mittels dieser bioverfüg baren, reparativen Mechanismen Zellen, Regel- und Immun systeme sowie die Selbstheilungskräfte über die durch die hochkonzentrierte L-(+)-Milchsäuregaben physiolo gische Kompetenz des Dickdarmmilieus zu vitalisieren und zu stimulieren.The process in which the vegetable Mass in a total amount of 10 to 20 wt .-% in the aqueous solution is present and this mass and the Zuta before fermentation in the disintegration facility be filled, followed by another direction by the impact of the disintegrator or a mi krofeine crushing and thus a corresponding To cause digestion of the substances that make up the Vegetable mass is composed to increase the effectiveness to increase these substances and their mutual rea to reinforce it and thereby bioavail it ble, reparative mechanisms cells, regulatory and immune systems as well as the self-healing powers over the the highly concentrated L - (+) - lactic acids are given physiologically to vitalize the genetic competence of the colonic environment to stimulate.
Untersuchungen an Zerkleinerungsvorgängen haben gezeigt, daß die aufgewandte Energie bei bestimmten hochenergeti schen Verfahren größer ist als die Summe aus Zerkleine rungsarbeit und freigesetzter Wärme. Die Differenz ent spricht der Aktivierungsenergie. Sie ist im Mahlgut ge speichert und kann für verschiedene chemische und physi kochemische Folgereaktionen als Auslöser oder Reaktions verbesserung nutzbar gemacht werden, indem sie den Schwellenwert der betreffenden Reaktionen herabsetzt bzw. diese beschleunigt. (Altmeri, Hint, Entzmann).Investigations of comminution processes have shown that the energy expended at certain high energy rule is greater than the sum of crumbs work and released heat. The difference ent speaks the activation energy. It is ge in the regrind stores and can be used for various chemical and physi Kochemische follow-up reactions as a trigger or reaction improvement can be harnessed by Threshold of the reactions concerned or this accelerates. (Altmeri, Hint, Entzmann).
Die vegetabile Masse aus bestimmten Heilpflanzen, rote Beete, bestimmten Früch ten u. dgl., die durch Desintegration mikrofein zerklei nert und dispergiert und aktiviert wird, dient Mikroor ganismen als Nährsubstrat, so daß sich die Zahl der Mi kroben bei optimalen Inkubations-Bedingungen etwa alle 30 Minuten verdoppelt. Dies wiederum wirkt sich auf die Leistungsfähigkeit der Biomasse im Sinne einer Steige rung der Stoffwechsel-Produktion und somit auf die Kon zentration der Gesamtmilchsäure von 4 bis 6 Gew.-% aus.The vegetable mass of certain medicinal plants, beetroot, certain fruits ten u. Like., The zerklei by disintegration of microfine nert and dispersed and activated, serves Mikroor organisms as a nutrient substrate, so that the number of Mi incubate at optimal incubation conditions about all Doubled for 30 minutes. This in turn affects the Performance of biomass in the sense of a crate tion of metabolism production and thus on the Kon concentration of total lactic acid from 4 to 6 Wt .-% off.
So haben Versuchsergebnisse mit der Desintegrations- Technologie gezeigt, daß bei mechanisch aktivierten Nährkomponenten wie Glukose, Fruktose, Lactose, Saccha rose, Tryptophan u. ä. noch bei Konzentration der Bio masse von 0,002%, 0,1%, 0,5-1% gegenüber nicht akti vierten Nährkomponenten, die Biomasse alle 30 Minuten eine Verdoppelung erfährt.Thus, test results with the disintegration Technology shown to be mechanically activated Nutrient components such as glucose, fructose, lactose, saccha rose, tryptophan u. Ä. Still at concentration of bio mass of 0.002%, 0.1%, 0.5-1% compared to non-active fourth nutrient components, the biomass every 30 minutes undergoes a duplication.
Als Indikationsobjekte erwiesen sich am günstigsten Mikroorganismen.As indication objects proved to be most favorable Microorganisms.
Folgende Stämme kamen u. a. zum Einsatz:
Staphylococcus citrus, Staphylococcus aureus, Strepto
coccus faecalis, Escherichia coli, L. acidophilus, Bac
terium bifidum, Saccharomyces champagner u. a.The following strains were used:
Staphylococcus citrus, Staphylococcus aureus, Streptococcus faecalis, Escherichia coli, L. acidophilus, Bacium bifidum, Saccharomyces champagner, and others
Beim Dispergieren der Nährkomponenten wurden relative Geschwindigkeiten bis 270 m/sec. gefahren. Die Inkuba tionszeit betrug zwischen 24 und 48 Stunden bei Tempe raturen von 37°C und 42°C. Die Anzahl der Mikroben wur den u. a. auf Agarmedium durch Zählung der Kolonien fest gestellt. Die Hefe-Mikroben wurden mittels der Gorjeav- Kammer gezählt.When dispersing the nutrient components were relative Speeds up to 270 m / sec. hazards. The Inkuba tion time was between 24 and 48 hours at Tempe temperatures of 37 ° C and 42 ° C. The number of microbes was wur the u. a. on agar medium by counting the colonies posed. The yeast microbes were extracted by means of the Gorjeav Chamber counted.
Im folgenden wird ein Beispiel für einige Bestandteile der Gesamtmenge an vegetabiler Masse angegeben, und zwar in prozentualen Gewichtsanteilen, bezogen auf ca. 100 kg Rohmassengemisch:The following is an example of some components the total amount of vegetable matter indicated, and although in percentages by weight, based on approx. 100 kg raw mixture mixture:
Im Hinblick auf die Zutaten zur vegetabilen Masse be trägt beispielsweise der Anteil der Vitamine u. a. zur Versorgung der Zellen über die Assimilation in 100 ml Fertigprodukt max. 165 mg Vitamin C, 33 mg Vitamin E, 30 mg Niacin, 4,3 mg Vitamin B₁, 4,3 mg Vitamin B₂ und 5 mg Vitamin B₆, was bei einer täglichen Einnahme von max. 30 ml Fertigprodukt etwa dem halben Deckungs bedarf pro Tag für einen Erwachsenen entspricht, bei einem Gesamtmilchsäuregehalt von mindestens 74% L-(+)- Milchsäure bzw. ca. mindestens 4,2% bis max. 4,8% Gesamtmilchsäure in 100 ml Fertigprodukt und einem pH-Wert 2,9 bis mindestens 3,4.With regard to the ingredients for the vegetable mass be For example, the proportion of vitamins u. a. to Supplying the cells via assimilation in 100 ml Finished product max. 165 mg vitamin C, 33 mg vitamin E, 30 mg niacin, 4.3 mg vitamin B₁, 4.3 mg vitamin B₂ and 5 mg of vitamin B₆, which is taken daily by Max. 30 ml of finished product about half coverage needs per day for an adult equivalent, at a total lactic acid content of at least 74% L - (+) - Lactic acid or about at least 4.2% to max. 4.8% total lactic acid in 100 ml of finished product and one pH 2.9 to at least 3.4.
Bei der Bearbeitung der vegetabilen Masse und der Zuta
ten (Massengemisch) in einer Desintegrationsanlage voll
ziehen sich drei entscheidende meßbare Phänomene:
In einem homöopathischen Mono-Arzneimittel, welches
z. B. Bestandteile von alkoholischen Lösungen bzw. Aus
züge aus Heilpflanzen in potenzierten Verdünnungen mit
Ethanol (z. B. D1, D6, D12, D30, D200) nach der Hahne
mann'schen Lehre enthält, sind in den hohen Potenzen
die pflanzlichen Anteile kaum noch analysierbar.When processing the vegetable mass and the ingredients (mass mixture) in a disintegration plant, three crucial measurable phenomena are present:
In a homeopathic mono-drug, which z. If, for example, constituents of alcoholic solutions or extracts from medicinal plants in potentiated dilutions with ethanol (eg D1, D6, D12, D30, D200) according to Hahne mann's doctrine are contained in the high potencies, the plant components hardly still analyzable.
Durch das Prinzip der mechanischen oder manuellen Ver schüttelung der in alkoholischer Basis gelösten Auszü ge werden deren pflanzliche Informationen (Botenstoffe) bis in die hohen Potenzen weitergegeben und bleiben dort verfügbar.By the principle of mechanical or manual Ver Shake the extract dissolved in alcoholic base their plant information (messenger substances) passed on to the high potencies and stay available there.
Dies gelang bisher nur im alkoholischen Milieu. Durch das Prinzip der Verschüttelung entsteht zur Informa tion ein meßbares bio-energetisches Terrain (Micro strahlungen/Schwingungen). Information und begrenzte bio-energetische Schwingungen als Auswirkung des Ver schüttelungseffektes stimulieren Regelmechanismen der Organe und Zellaktivität.So far, this has only been possible in the alcoholic milieu. By the principle of shaking arises to Informa a measurable bio-energetic terrain (Micro radiations / vibration). Information and limited Bio-energetic vibrations as an effect of Ver shaking effect stimulate regulating mechanisms of the Organs and cell activity.
Problematisch bleibt für Kleinkinder, Jugendliche, An tialkoholiker, Alkoholgefährdete, gereatrische Menschen der in den homöopathischen Arzneimitteln bis zu 64 Vol.-% vorhandene Alkohol.The problem remains for toddlers, young people, An alcoholics, alcoholics, geriatric people in homeopathic medicines up to 64 Vol .-% of existing alcohol.
Durch das Herstellungsverfahren mit der Desintegrationseinrichtung werden in der Relation zur voluminösen hydrophilen Phase ebenfalls relativ geringfügige Quantitäten an natürlichen Heilpflanzen und anderen Zutaten verwendet.By the manufacturing process with the disintegration device will be in the relation relative to the voluminous hydrophilic phase as well small quantities of natural medicinal plants and other ingredients used.
Während bei den homöopathischen Drogenauszügen die vom menschlichen Organismus benötigten wertvollen pflanzli chen Eiweiß- und Mineralienbausteine der Pflanzen nicht voll vorhanden sind, verbleiben diese Wirkstoffe durch die mikrofeine Dispersion der ganzen Pflanzen vollstän dig im enzymatischen Stoffwechselprodukt.While in the homeopathic drug extracts from the Human organism needed valuable plant protein and mineral components of plants are fully present, these agents remain through complete the microfine dispersion of the whole plants dig in the enzymatic metabolite.
Durch die Einwirkung der hohen Schlagzahl der rotieren den Schlagelemente und eines statischen oder dynamischen und/oder elektrischen Spannungsfeldes gelingt es erstma lig, trotz der quantitativ geringen vegetabilen Vital stoffanteile deren Information (Botenstoffe) in eine hydrophile Phase zu integrieren, was mit bio-energeti schen Messungen festgestellt werden konnte.Rotate by the action of the high rate of impact the striking elements and a static or dynamic and / or electrical voltage field succeeds erstma oily, despite the quantitatively low vegetable vitality their information (messenger substances) in a to integrate hydrophilic phase, what with bio-energeti could be determined.
Bio-energetische Terrain-Vergleichsmessungen zwischen homöopathischen Arzneimitteln und dem hydrophilen enzy matischen Stoffwechselprodukt haben ein bis zu 180 bis 200% höheres bio-energetisches Schwingungsfeld aufge zeigt.Bio-energetic terrain comparison measurements between homeopathic medicines and the hydrophilic enzy matic metabolite have a up to 180 to 200% higher bio-energetic oscillation field shows.
In der Anwendungspraxis bedeutet ein höheres bio-ener getisches Schwingungsfeld, wobei die im Massengemisch des enzymatischen Stoffwechselproduktes durch Beimpfung mit Kulturen erzeugte L-(+)-Milchsäure auch als Adapter tätig wird, eine spezifische optimale Resorption und As similation der bio-verfügbaren Information bzw. der Bo tenstoffe zur Stimulierung der teilweise blockierten oder fehlgesteuerten Regelsysteme zu regenerierenden Zellaktivitäten und Auslösung der Selbstheilungskräf te. Das Problem Alkohol ist nicht mehr relevant.In practice, a higher bio-ener means genetic vibrational field, wherein the mass mixture of the enzymatic metabolite by inoculation cultures produced L - (+) - lactic acid also as an adapter becomes active, a specific optimal absorption and As Similation of bio-available information or Bo substances to stimulate the partially blocked or faulty control systems to be regenerated Cell activities and triggering of the Selbstheilungskräf te. The problem of alcohol is no longer relevant.
Die Trägerphase der Information bzw. der Botenstoffe, nämlich das Tiefbrunnenwasser, so haben Messungen ergeben, besitzt so gut wie kein bio-energe tisches Terrain.The carrier phase of the information or the messenger substances, namely the deep well water, so have Measurements reveal virtually no bio-energy table terrain.
Erst durch das Herstellungsverfahren mittels der Desintegrationseinrichtung - also durch Dispersion und mechano-chemische Aktivierung - gelingt es, durch Einwirkung der rotierenden Schlagelemente mit entsprechend hoher Schlagzahl und eines statischen oder dynamischen und/oder elektrischen Spannungsfeldes ein bio-energetisches Terrain, ausgewiesen durch hohe bio-energetische Schwingungen, im Tiefbrunnenwasser für immer zu integrieren.Only through the manufacturing process by means of the disintegration device - ie by Dispersion and mechano-chemical activation - succeed it, by the action of the rotating impact elements with a correspondingly high number of hits and a static one or dynamic and / or electrical stress field a bio-energetic terrain, characterized by high bio-energetic vibrations, in deep well water for always integrate.
Somit wird erfindungsgemäß ein enzymatisches Stoffwech selprodukt aus darmresidenten Lacto- udn Bifido-Bakte rien zur Gewinnung hochkonzentrierter L-(+)-Milchsäure zur Rückführung eines entgleisten Dickdarm-pH-Wertes in den Normbereich und Fermentation einer vegetabilen Masse zur Endversorgung der Zellen und deren Sauerstoff- Utilisation entwickelt, das sicherstellt, daß die Stoff wechselaktivitäten Gallensäure dekonjungierender Clo stridienkeime und ammoniakgasbildender Fäulnisfloren das stoffwechseloptimale pH-Milieu entzogen wird, Ent giftungs-, Resorptions- und Stoffwechselfunktionen des Darms wieder in einem ausreichenden Maße erfüllt werden und die immunologischen Abläufe sowie die Selbsthei lungskräfte aktiviert, so daß Obstipationen, colon ir ritabile, Völlegefühl, Gasbildung, Flatulenz und Müdig keit sowie die durch diese Symptome erfolgende Auslösung stoffwechselabhängiger Zivilisationskrankheiten mit ih ren gefürchteten Komplikationen vermieden werden.Thus, according to the invention, an enzymatic metabolism selprodukt from intestinal lacto- and Bifido-Bakte to obtain highly concentrated L - (+) - lactic acid to return a derailed colonic pH in the normal range and fermentation of a vegetable Mass for the final supply of the cells and their oxygen Utilization develops, which ensures that the substance bile acid deconciding clo stridium germs and ammonia gas-forming decaying floras the metabolism-optimal pH environment is removed, Ent poisoning, absorption and metabolic functions of the Darms be met again to a sufficient extent and the immunological processes as well as the self-healing activated, so that constipations, colon ir Ritabile, fullness, gas, flatulence and tired and the triggering of these symptoms metabolism-dependent civilization diseases with ih avoid dreaded complications.
Claims (4)
Tiefbrunnenwasser, Süßmolke-Konzentrat, Blütenpollen, Brennessel, Löwenzahn, schmalblättriger Sonnenhut, rote Beete, Heidelbeeren, schwarze Johannisbeere und Karotten, in einer Gesamtmenge von 10-20 Gew.-%,
und die Zutaten bestehen aus:
Kaliumverbindungen, Calciumverbindungen, Eisenverbin dungen, Vitamin d1-E-acetat, B₁, B₂, B₆, Niacin und Ascorbinsäure,
und der Anteil der Vitamine in der Tagesdosis von 30 ml dem halben täglichen Deckungsbedarf für einen Erwachsenen ent spricht, die Gesamtmilchsäure 4 bis 6 Gew.-% und der pH-Wert 2,9 bis 3,4 betragen, wobei die vegetabile Masse und die Zu taten vor der Vergärung in einer Desintegrationseinrichtung durch eine mechano-chemische Reaktion mittels rotierender Schlagelemente mikrofein zerkleinert, dispergiert und akti viert werden. 1. Enzymatic metabolite from similar, non-pathogenic, intestinal lacto- and Bifido bacteria, which as cultures the mass mixture at the required species for the relevant species average temperature and in incubation time to obtain highly concentrated L - (+) - lactic acid and fermentation of a vegetable mass to the final supply the cells and their oxygen Utilisa tion are added, consisting of the vegetable mass, mineral salts and vitamins, wherein the vaginal mass composed as an aqueous solution of the following vegetable and vital substances:
Deep well water, sweet whey concentrate, bee pollen, stinging nettle, dandelion, coneflower hat, beetroot, blueberry, blackcurrant and carrots, in a total amount of 10-20% by weight,
and the ingredients are:
Potassium compounds, calcium compounds, iron compounds, vitamin d1-E-acetate, B₁, B₂, B₆, niacin and ascorbic acid,
and the proportion of vitamins in the daily dose of 30 ml corresponds to half the daily cover requirement for an adult, the total lactic acid 4 to 6 wt .-% and the pH 2.9 to 3.4, wherein the vegetable mass and the To be done before fermentation in a disintegration by a mechano-chemical reaction by means of rotating impact elements microfine crushed, dispersed and acti fourth.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4132296A DE4132296C1 (en) | 1991-09-27 | 1991-09-27 | Enzymic metabolic prod. prepn. for intestinal disorders etc. - obtd. from pathogenic lacto- and bifido- bacteria from the gut |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4132296A DE4132296C1 (en) | 1991-09-27 | 1991-09-27 | Enzymic metabolic prod. prepn. for intestinal disorders etc. - obtd. from pathogenic lacto- and bifido- bacteria from the gut |
Publications (1)
Publication Number | Publication Date |
---|---|
DE4132296C1 true DE4132296C1 (en) | 1992-12-17 |
Family
ID=6441676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE4132296A Expired - Fee Related DE4132296C1 (en) | 1991-09-27 | 1991-09-27 | Enzymic metabolic prod. prepn. for intestinal disorders etc. - obtd. from pathogenic lacto- and bifido- bacteria from the gut |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE4132296C1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000007606A2 (en) * | 1998-08-07 | 2000-02-17 | Ganeden Biotech, Inc. | Methods for increasing the solubility of nutritional materials using probiotic lactic acid-producing bacteria |
WO2000010582A2 (en) * | 1998-08-24 | 2000-03-02 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
JP2004026840A (en) * | 2003-08-01 | 2004-01-29 | Nitto Yakuhin Kogyo Kk | Viable bacterium composition |
EP1719518A1 (en) * | 1998-08-07 | 2006-11-08 | Ganeden Biotech, Inc. | Compositions comprising bacillus coagulans for increasing the solubility and bioavailability of nutritional minerals |
US7700093B2 (en) | 2003-12-05 | 2010-04-20 | Ganeden Biotech, Inc. | Methods for increasing lactose digestion |
WO2010079104A1 (en) * | 2009-01-07 | 2010-07-15 | Chr. Hansen A/S | Additive to food or drinking water containing botanical antioxidants together with probiotic microorganisms |
EP2292105A1 (en) | 2009-09-08 | 2011-03-09 | Hölzel, Evelyn | Dietetic product |
US9446111B2 (en) | 2009-04-29 | 2016-09-20 | Ganeden Biotech, Inc. | Inactivated bacterial cell formulation |
US9622502B2 (en) | 2008-10-16 | 2017-04-18 | Ganeden Biotech, Inc. | Probiotic Bacillus pasta compositions |
US10383342B2 (en) | 2007-08-29 | 2019-08-20 | Ganeden Biotech, Inc. | Baked goods |
US11235008B2 (en) | 2011-03-31 | 2022-02-01 | Ganeden Biotech, Inc. | Probiotic sports nutrition compositions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4032730A1 (en) * | 1989-10-16 | 1991-04-18 | Karl Heinz Hoelzel | Enzymatic metabolic material for treating gastrointestinal disorders - produced from intestinal lacto- and bifido-bacteria, which are used to ferment a vegetable mass |
-
1991
- 1991-09-27 DE DE4132296A patent/DE4132296C1/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4032730A1 (en) * | 1989-10-16 | 1991-04-18 | Karl Heinz Hoelzel | Enzymatic metabolic material for treating gastrointestinal disorders - produced from intestinal lacto- and bifido-bacteria, which are used to ferment a vegetable mass |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8273346B2 (en) | 1998-08-07 | 2012-09-25 | Ganeden Biotech, Inc. | Method for increasing fructose digestion with strains of Bacillus coagulans and fructase |
WO2000007606A2 (en) * | 1998-08-07 | 2000-02-17 | Ganeden Biotech, Inc. | Methods for increasing the solubility of nutritional materials using probiotic lactic acid-producing bacteria |
EP1719518A1 (en) * | 1998-08-07 | 2006-11-08 | Ganeden Biotech, Inc. | Compositions comprising bacillus coagulans for increasing the solubility and bioavailability of nutritional minerals |
US8343484B2 (en) | 1998-08-07 | 2013-01-01 | Ganeden Biotech, Inc. | Methods for increasing lactose and fructose digestion |
US7767203B2 (en) | 1998-08-07 | 2010-08-03 | Ganeden Biotech, Inc. | Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
WO2000007606A3 (en) * | 1998-08-07 | 2000-05-18 | Ganeden Biotech Inc | Methods for increasing the solubility of nutritional materials using probiotic lactic acid-producing bacteria |
US8097247B2 (en) | 1998-08-24 | 2012-01-17 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
US7807151B2 (en) | 1998-08-24 | 2010-10-05 | Ganeden Biotech, Incorporated | Probiotic, lactic acid-producing bacteria and uses thereof |
US8697055B2 (en) | 1998-08-24 | 2014-04-15 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria |
US7708988B2 (en) | 1998-08-24 | 2010-05-04 | Ganeden Biotech, Incorporated | Probiotic, lactic acid-producing bacteria and uses thereof |
US8187590B2 (en) | 1998-08-24 | 2012-05-29 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
WO2000010582A2 (en) * | 1998-08-24 | 2000-03-02 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
WO2000010582A3 (en) * | 1998-08-24 | 2000-07-13 | Ganeden Biotech Inc | Probiotic, lactic acid-producing bacteria and uses thereof |
JP2004026840A (en) * | 2003-08-01 | 2004-01-29 | Nitto Yakuhin Kogyo Kk | Viable bacterium composition |
US10111916B2 (en) | 2003-12-05 | 2018-10-30 | Ganeden Biotech, Inc. | Compositions comprising Bacillus coagulans spores and whey |
US7700093B2 (en) | 2003-12-05 | 2010-04-20 | Ganeden Biotech, Inc. | Methods for increasing lactose digestion |
US10383342B2 (en) | 2007-08-29 | 2019-08-20 | Ganeden Biotech, Inc. | Baked goods |
US11419355B2 (en) | 2008-10-16 | 2022-08-23 | Ganeden Biotech, Inc. | Probiotic grain-based compositions |
US9622502B2 (en) | 2008-10-16 | 2017-04-18 | Ganeden Biotech, Inc. | Probiotic Bacillus pasta compositions |
US10321704B2 (en) | 2008-10-16 | 2019-06-18 | Ganeden Biotech, Inc. | Probiotic grain-based compositions |
WO2010079104A1 (en) * | 2009-01-07 | 2010-07-15 | Chr. Hansen A/S | Additive to food or drinking water containing botanical antioxidants together with probiotic microorganisms |
US9446111B2 (en) | 2009-04-29 | 2016-09-20 | Ganeden Biotech, Inc. | Inactivated bacterial cell formulation |
US9757442B2 (en) | 2009-04-29 | 2017-09-12 | Ganeden Biotech, Inc. | Inactivated bacterial cell formulation |
DE102009040571A1 (en) | 2009-09-08 | 2011-03-24 | Hölzel, Evelyn | dietetic |
EP2292105A1 (en) | 2009-09-08 | 2011-03-09 | Hölzel, Evelyn | Dietetic product |
US11235008B2 (en) | 2011-03-31 | 2022-02-01 | Ganeden Biotech, Inc. | Probiotic sports nutrition compositions |
US11351206B2 (en) | 2011-03-31 | 2022-06-07 | Ganeden Biotech, Inc. | Probiotic sports nutrition compositions |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69838988T2 (en) | METHOD AND COMPOSITIONS USING RED RICE FERMENTATION PRODUCTS | |
DE69733215T2 (en) | ANTI-STRESS ACTIVE SUBSTANCES AND FUNCTIONAL NUTRIENTS WITH ANTI-STRESS EFFECTS | |
DE4132296C1 (en) | Enzymic metabolic prod. prepn. for intestinal disorders etc. - obtd. from pathogenic lacto- and bifido- bacteria from the gut | |
DE102006062250A1 (en) | Use of a composition of minerals and / or vitamins and optionally acetogenic and / or butyrogenic bacteria for oral or rectal administration for the treatment and prevention of abdominal discomfort | |
CH701253A1 (en) | Use of an extract from snow algae in cosmetic or dermatological formulations. | |
EP0195213B1 (en) | Lactic acid containing fruit products and process for lactic fermentation of fruit products | |
DE60005104T2 (en) | DIET ADDITIVE FROM FERMENTED MILK PRODUCTS FOR PREVENTING ÖSTEOPOROSIS | |
DE1642578C3 (en) | Process for the preparation of an enzymatic composition having proteolytic enzyme and collagenase activity | |
EP1952703B1 (en) | Product including living probiotic micro organisms | |
EP0357162A2 (en) | Process for modifying whey | |
DE10042625A1 (en) | Deodorizing apparatus for sewage line, has deodorizing tower with deodorizing layer, catalytic reaction tower with catalyst for reacting catalyst with deodorized gas to form odorless gas | |
EP2560506A1 (en) | Process for producing a fermented natural product | |
DD282706C4 (en) | METHOD FOR PRODUCING A BIOPHYSICALLY DERIVATIVED HEFEPRAEPARATE WITH A BREATHABLE ACTIVITY, THESE INGREDIENT AND PLANT GROWTH SUBSTANCES, AND THEIR USE | |
DE2414156A1 (en) | MEDICINAL PRODUCTS FOR THE ELIMINATION OF URAEMIC SYMPTOMS AND THE METHOD OF MANUFACTURING IT | |
DE69634917T2 (en) | MILKY ACID BACTERIA AND ITS APPLICATION FOR THE PREPARATION OF HYPERCHOLESTEROLEMIC ACTIVE PRODUCTS | |
CH647945A5 (en) | Lyophilised, enzymatically degraded sour milk product | |
CH712713A2 (en) | Maca-enriched coffee and process for its preparation. | |
EP0482530B1 (en) | Composition for the regulation of intestinal flora | |
EP2132994B1 (en) | Fermentation of solutions containing pomegranate juice with saccharomyces boulardii and lactobacilli, resulting fermented products and application thereof | |
WO1996035439A1 (en) | Low molecular yeast active substance extract and process for preparing the same | |
EP2292105B1 (en) | Dietetic product | |
DE4032730A1 (en) | Enzymatic metabolic material for treating gastrointestinal disorders - produced from intestinal lacto- and bifido-bacteria, which are used to ferment a vegetable mass | |
DE69634542T2 (en) | USE OF A DEHYDRATED PREPARATION OF PROPIONIC BACTERIA FOR PREPARING A DIETETIC COMPOSITION FOR IMPROVING THE BIOLOGICAL BALANCE OF THE DARMFLORA | |
KR20210026948A (en) | Cream-type cosmetic composition containing cactus extract | |
CN107811251A (en) | A kind of red pears composite enzyme of honey and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8100 | Publication of the examined application without publication of unexamined application | ||
D1 | Grant (no unexamined application published) patent law 81 | ||
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: HOELZEL, EVELYN, 86946 VILGERTSHOFEN, DE |
|
8381 | Inventor (new situation) |
Free format text: HOELZEL, KARL HEINZ, 82296 SCHOENGEISING, DE |
|
R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |
Effective date: 20110401 |